Recombinant Mouse Activin receptor type-2B (Acvr2b)

What is Activin Receptor Type-2B and what are its primary functions?

Activin receptor type-2B (Acvr2b) is a type II serine/threonine kinase receptor that plays a crucial role in the TGF-beta superfamily signaling pathway. The mature mouse Acvr2b consists of a 119 amino acid extracellular domain, a 21 amino acid transmembrane segment, and a 378 amino acid cytoplasmic region that includes the kinase domain and a C-terminal PDZ-binding motif . Functionally, Acvr2b mediates signal transduction by binding ligands such as activins, after which it associates with type I receptors to initiate downstream signaling cascades .

Acvr2b plays a significant role in regulating muscle mass development. Studies have shown that targeting Acvr2b in muscle fibers results in increases in muscle mass of approximately 8-12% in females and 4-6% in males, depending on the specific muscle examined . This receptor is particularly important in myostatin (MSTN) signaling, which is a negative regulator of skeletal muscle growth.

How does Acvr2b compare structurally across species?

The Acvr2b receptor shows remarkable conservation across species. Within the extracellular domain (ECD), mouse Acvr2b shares 99% amino acid sequence identity with human and rat Acvr2b . Comparative analysis with other species reveals that sea bream Acvr2b shares 63% sequence similarity with several mammalian Acvr2b proteins, including those from chimpanzees, humans, cattle, rats, and mice . Lower sequence similarity has been observed with zebrafish Acvr2b (59%) and goldfish (57%) .

This high degree of conservation underscores the evolutionary importance of this receptor in regulating fundamental biological processes across vertebrate species. The structural conservation particularly in the ligand-binding domains suggests similar functional mechanisms across diverse organisms.

What ligands interact with Acvr2b and with what affinities?

Acvr2b binds multiple ligands from the TGF-beta superfamily with varying affinities. While activin isoforms bind with particularly high affinity, Acvr2b also interacts with:

• Activin isoforms (A, B, and AB)

• Growth Differentiation Factor 11 (GDF11/BMP11)

• Myostatin (GDF8)

• Inhibin

• Bone Morphogenetic Protein 2 (BMP-2)

• Bone Morphogenetic Protein 7 (BMP-7)

The affinity of these interactions varies by ligand and receptor isoform. Different activin isoforms bind with different high affinities to the various type II receptor isoforms . The lower affinity interactions with inhibin, BMP-2, and BMP-7 suggest a more nuanced regulatory role in contexts where these ligands predominate.

What methods are used to express and purify recombinant mouse Acvr2b?

Common methodologies for expression and purification of recombinant mouse Acvr2b involve:

• Expression systems: Mammalian cell lines (commonly Chinese Hamster Ovary cells), yeast systems (Pichia pastoris), or insect cell expression systems.

• Construct design: Typically involves creating a chimeric protein with the extracellular domain of Acvr2b fused to an Fc region of human IgG to increase stability and facilitate purification. This creates the Acvr2b-Fc chimera protein .

• Purification process: Standard purification involves affinity chromatography exploiting the Fc tag, followed by additional chromatography steps to achieve high purity (≥95%) .

• Quality control: Verification through SDS-PAGE under reducing and non-reducing conditions, with recombinant mouse Acvr2b Fc chimera showing bands at approximately 63 kDa under reducing conditions and 110 kDa under non-reducing conditions .

For optimal biological activity, the purified protein should be tested in functional assays, such as inhibition of Activin A-induced hemoglobin expression in the K562 human chronic myelogenous leukemia cell line .

How do Acvr2 and Acvr2b function redundantly in muscle mass regulation?

Genetic studies have definitively demonstrated that Acvr2 and Acvr2b are functionally redundant with respect to limiting muscle mass. Targeting either receptor alone in muscle fibers produces modest increases in muscle mass, but targeting both receptors simultaneously results in substantially greater muscle growth .

• 58% increase in quadriceps muscle in females

• 50% increase in quadriceps muscle in males

• 72% increase in gastrocnemius muscle in females

• 62% increase in gastrocnemius muscle in males

These findings conclusively establish that myofibers are the primary direct target for signaling by myostatin in regulating muscle growth, and that both Acvr2 and Acvr2b contribute to this regulation .

What are the implications of type II/type I receptor combinations in Acvr2b signaling?

Research has revealed that all four possible combinations of type II and type I receptors (ACVR2/ALK4, ACVR2/ALK5, ACVR2B/ALK4, and ACVR2B/ALK5) are utilized in vivo for signaling that regulates muscle mass . To determine the role of each combination, researchers targeted these receptors pairwise (one type II receptor with one type I receptor).

Key findings include:

• Targeting both Acvr2b and Alk5 resulted in greater muscle mass increases than targeting either alone, indicating that the ACVR2/ALK4 combination cannot be solely responsible for signaling in vivo.

• The increases observed in these mice did not approach those seen in mice lacking both type II receptors or both type I receptors, suggesting that ACVR2/ALK4 does contribute to signaling.

• The most significant effects were observed when both Acvr2 and Alk5 were targeted, resulting in muscle mass increases of approximately 40% in some muscles. This suggests that the ACVR2B/ALK4 combination is the least important of the four in limiting muscle growth .

• These increases were still significantly less than those seen when targeting both Acvr2 and Acvr2b together, indicating that the ACVR2B/ALK4 combination does play some role in myofiber growth regulation .

This complex interplay of receptor combinations highlights the redundancy and robustness of the signaling mechanisms controlling muscle mass development.

How does Acvr2b signaling interact with bone development pathways?

Research has shown that Acvr2b signaling affects not only muscle mass but also bone mineral density. Administration of a soluble form of the activin type IIB receptor (ACVR2B/Fc) systemically to mice increases both muscle mass and bone mineral density .

This effect appears to operate through two mechanisms:

• Direct signaling to bone: Targeting Acvr2 and Acvr2b in osteoblasts is sufficient to increase bone density in vivo, likely through inhibition of activin A signaling .

• Indirect effects: Increased muscle mass resulting from inhibition of signaling to myofibers may place greater mechanical load on bones, thereby contributing to increased bone density .

To distinguish between these mechanisms, researchers compared the bones of mice in which Acvr2 and Acvr2b were targeted in myofibers to those of wild-type mice, cre-negative mice, and mice receiving the ACVR2B/Fc decoy receptor. Systemic administration of ACVR2B/Fc induced rapid and significant muscle growth, with individual muscle weights increasing by approximately 40-50% over a 5-week treatment period .

This dual effect on muscle and bone highlights the potential therapeutic implications of targeting Acvr2b signaling in conditions affecting both muscle and bone health.

What are the methodological challenges in developing effective Acvr2b-Fc proteins for research applications?

Researchers face several methodological challenges when developing Acvr2b-Fc fusion proteins:

• Optimizing biological activity: The ED50 for inhibiting Activin A-induced effects can vary (5-30 ng/mL in the presence of 3 ng/mL of Recombinant Human/Mouse/Rat Activin A), requiring careful calibration for experimental use .

• Maintaining protein stability: The chimeric nature of Acvr2b-Fc proteins necessitates careful handling to preserve structure and function. Under reducing conditions, the protein shows bands at 63 kDa, while under non-reducing conditions, it displays bands at 110 kDa, reflecting its dimeric structure .

• Managing receptor modulation by accessory proteins: Acvr2b-mediated signaling can be modulated by several accessory proteins that must be considered:

  • Interactions with GPI-linked RGM-A/DRAGON lower the threshold for BMP-2 and BMP-4 induced signaling

  • Acvr2b forms a ternary complex with activin A and cripto that prevents association with the type I receptor ActRIB

  • Acvr2b can form a ternary complex with activin A and endoglin

  • The C-terminal tail of Acvr2b specifically binds the PDZ domain of ARIP2, enhancing receptor internalization

These interactions add complexity to experimental designs utilizing recombinant Acvr2b-Fc proteins and must be carefully controlled or accounted for in research applications.

What are the optimal experimental systems for studying Acvr2b function in muscle development?

When designing experiments to study Acvr2b function in muscle development, researchers should consider the following systems and approaches:

• In vivo mouse genetic models:

  • Conditional knockout models using the Cre-loxP system to target Acvr2b specifically in muscle fibers (e.g., using Myl1-cre)

  • Double knockout models targeting both Acvr2 and Acvr2b to overcome functional redundancy

  • Transgenic models expressing truncated forms of Acvr2b lacking the kinase domain

• Soluble receptor approaches:

  • Administration of soluble Acvr2b-Fc fusion proteins to block ligand binding

  • Adeno-associated virus-mediated gene transfer of soluble Acvr2b

• Cell culture systems:

  • K562 human chronic myelogenous leukemia cell line for assessing inhibition of Activin A-induced hemoglobin expression

  • Primary myoblast cultures for studying myoblast-to-myotube differentiation

  • C2C12 mouse myoblast cell line for studying muscle differentiation

• Readout measurements:

  • Muscle mass quantification

  • Histological assessment of muscle fiber size

  • RNA expression analysis of target genes

  • Protein phosphorylation analysis of downstream signaling components

The choice of experimental system should be guided by the specific research question, with consideration given to the redundancy between Acvr2 and Acvr2b.

How can researchers accurately quantify Acvr2b expression and activity?

Accurate quantification of Acvr2b expression and activity is essential for robust experimental outcomes. Recommended methodologies include:

• RNA expression analysis:

  • Quantitative RT-PCR using specific primers for Acvr2b

  • RNA sequencing for genome-wide expression analysis

  • In situ hybridization for spatial localization of expression

• Protein expression analysis:

  • Western blotting using specific antibodies against Acvr2b

  • Immunohistochemistry or immunofluorescence for tissue localization

  • Flow cytometry for cell-specific expression analysis

• Functional activity assays:

  • Inhibition of Activin A-induced hemoglobin expression in K562 cells

  • Smad2/3 phosphorylation assays to measure downstream signaling

  • Reporter gene assays with Smad-responsive elements

  • Analysis of target gene expression (e.g., muscle-specific genes)

• Binding assays:

  • Surface plasmon resonance to measure binding affinity to ligands

  • Co-immunoprecipitation to detect complex formation with type I receptors

  • Crosslinking studies to identify binding partners

When analyzing Acvr2b expression in muscle tissue, researchers should account for potential expression by non-muscle cells and type I fibers, which may contribute to residual expression even after targeted deletion in muscle fibers .

What controls and validation steps are essential when using recombinant Acvr2b in research?

To ensure experimental rigor when working with recombinant Acvr2b, researchers should implement the following controls and validation steps:

• Protein quality controls:

  • SDS-PAGE analysis under reducing and non-reducing conditions to confirm expected molecular weights (63 kDa and 110 kDa, respectively)

  • Mass spectrometry to verify protein identity and purity

  • Endotoxin testing to ensure preparations are endotoxin-free

• Functional validation:

  • Dose-response curves in established bioassays (e.g., K562 cell assay)

  • Comparison with established reference standards

  • Verification of binding to known ligands

• Experimental controls:

  • Include non-treated controls in all experiments

  • Use isotype-matched control proteins for Fc-fusion proteins

  • Include both positive controls (known activators) and negative controls

• Specificity controls:

  • Test for cross-reactivity with other receptor types

  • Include receptor knockout cells/tissues as negative controls

  • Perform competitive binding assays to confirm specificity

• Reproducibility measures:

  • Use multiple protein batches to ensure consistent results

  • Perform independent biological replicates

  • Document and report all experimental conditions thoroughly

These validation steps are crucial for ensuring that observed effects are specifically attributable to Acvr2b function rather than experimental artifacts.

How should researchers interpret phenotypic differences between Acvr2 and Acvr2b knockout models?

When interpreting phenotypic differences between Acvr2 and Acvr2b knockout models, researchers should consider several factors:

• Functional redundancy: The most significant finding from knockout studies is that Acvr2 and Acvr2b are functionally redundant with respect to muscle mass regulation. Single receptor knockouts show modest phenotypes, while double knockouts exhibit dramatic increases in muscle mass .

• Muscle-specific effects: Different muscles may show varying responses to receptor deletion. For example, targeting Acvr2 alone resulted in significant increases in quadriceps and gastrocnemius muscles but not in pectoralis or triceps muscles .

• Sex-specific differences: Female and male mice may show different magnitudes of response. For example, targeting Acvr2b alone resulted in muscle mass increases of 8-12% in females but only 4-6% in males .

• Residual expression: When interpreting the effects of conditional knockouts, researchers should consider that residual expression may occur in non-targeted cells within the tissue, such as type I fibers or non-muscle cells .

• Compensatory mechanisms: Check for compensatory up-regulation of other receptors. In the case of Acvr2 and Acvr2b, studies have shown that targeting one receptor does not lead to compensatory up-regulation of the other receptors .

This nuanced interpretation is essential for accurately understanding the biological roles of these receptors in vivo.

What statistical approaches are most appropriate for analyzing muscle hypertrophy in Acvr2b studies?

When analyzing muscle hypertrophy in Acvr2b studies, the following statistical approaches are recommended:

• Comparative analyses:

  • ANOVA with post-hoc tests for comparing multiple experimental groups

  • t-tests for direct comparisons between two groups

  • Mixed-effects models for longitudinal studies with repeated measurements

• Effect size calculations:

  • Percent change in muscle mass relative to control groups

  • Cohen's d or similar standardized effect size metrics

  • Calculation of the minimum detectable difference based on sample size and variation

• Correlation analyses:

  • Regression analysis to examine relationships between receptor expression levels and muscle mass

  • Correlation between muscle mass changes and functional outcomes

  • Factor analysis to identify patterns across multiple muscles or experimental conditions

• Sample size considerations:

  • Power analysis to determine appropriate sample sizes

  • Consideration of sex as a biological variable

  • Appropriate randomization and blinding procedures

• Data presentation:

  • Clear tables showing mean values, standard deviations, and sample sizes

  • Box plots or violin plots to show data distribution

  • Forest plots for meta-analyses of multiple studies

Researchers should report both the magnitude of effects (e.g., percent increase in muscle mass) and the statistical significance, while being mindful of biological significance beyond p-values.

How do researchers differentiate direct and indirect effects of Acvr2b inhibition?

Differentiating direct and indirect effects of Acvr2b inhibition is a complex challenge requiring multiple experimental approaches:

• Cell-type specific targeting:

  • Use of conditional knockout models with cell-type specific Cre recombinase expression

  • Comparison of systemic versus tissue-specific inhibition

  • In vitro studies with isolated cell populations

• Temporal analyses:

  • Time-course experiments to determine the sequence of events

  • Inducible knockout systems to control the timing of receptor deletion

  • Pulse-chase experiments to track cellular responses over time

• Pathway analysis:

  • Assessment of immediate downstream signaling events (e.g., Smad phosphorylation)

  • Transcriptomic analysis at multiple time points to identify primary and secondary response genes

  • Pharmacological inhibition of suspected intermediate pathways

• Combinatorial approaches:

  • Combined inhibition of multiple pathways to identify interactions

  • Rescue experiments by restoring specific pathways in knockout backgrounds

  • Cross-tissue analyses to identify systemic effects

A specific example from the research literature involves distinguishing direct and indirect effects of Acvr2b inhibition on bone. Researchers compared the effects of targeting Acvr2 and Acvr2b specifically in osteoblasts versus myofibers, as well as the effects of systemic administration of ACVR2B/Fc decoy receptor . This multi-pronged approach helped differentiate between direct signaling to bone and indirect effects resulting from increased mechanical load due to enhanced muscle mass.

What are the promising therapeutic applications of Acvr2b research for muscle-wasting disorders?

Research on Acvr2b has revealed several promising therapeutic applications for muscle-wasting disorders:

• Cancer cachexia treatment:

  • Administration of ACVR2B-ECD has been shown to not only prevent muscle wasting but also restore prior muscle loss in various cancer cachexia models .

  • This approach could potentially address the significant morbidity and mortality associated with cancer-related muscle wasting.

• Muscular dystrophy interventions:

  • Transgenic Mdx (Dystrophin-deficient) mice carrying a dominant negative Acvr2b gene exhibited larger muscles than Mdx mice with a normal Acvr2b gene .

  • This suggests potential interventions for Duchenne muscular dystrophy and related conditions.

• Age-related sarcopenia:

  • Inhibition of the myostatin/Acvr2b pathway could counteract age-related muscle loss.

  • Combined approaches targeting both muscle growth and regeneration may be particularly effective.

• Systemic delivery approaches:

  • Adeno-associated virus-mediated gene transfer of soluble forms of Acvr2b has shown promise as a delivery method .

  • Alternative delivery systems including modified mRNA, peptide mimetics, and small molecule inhibitors are areas of active investigation.

• Combinatorial therapies:

  • Combining Acvr2b inhibition with exercise regimens may provide synergistic benefits.

  • Pairing with nutritional interventions could address multiple facets of muscle maintenance.

These therapeutic applications highlight the translational potential of basic research on Acvr2b signaling for addressing clinically significant muscle-wasting conditions.

What are the unexplored areas in Acvr2b signaling and receptor biology?

Despite significant advances in understanding Acvr2b function, several areas remain underexplored:

• Receptor isoform specificity:

  • Acvr2b exists in four alternately spliced forms distinguished by deletion of juxtamembrane stretches in the extra and/or intracellular regions .

  • The specific biological roles of these isoforms remain incompletely characterized.

• Cross-talk with other signaling pathways:

  • Interactions between Acvr2b signaling and other pathways (e.g., insulin/IGF-1, inflammatory signaling) require further investigation.

  • The integration of mechanical and hormonal signals with Acvr2b activity presents opportunities for novel insights.

• Tissue-specific cofactors:

  • The C-terminal tail of Acvr2b specifically binds the PDZ domain of ARIP2, which enhances receptor internalization and hinders activin-induced responses .

  • Additional tissue-specific cofactors may exist and contribute to context-dependent signaling outcomes.

• Epigenetic regulation:

  • How epigenetic mechanisms influence Acvr2b expression and function across different physiological and pathological states.

  • The role of non-coding RNAs in modulating Acvr2b signaling.

• Evolutionary perspectives:

  • Comparative studies across species could reveal evolutionary adaptations in Acvr2b signaling related to different muscle phenotypes.

  • The functional implications of sequence differences between species (e.g., the 63% similarity between sea bream and mammalian Acvr2b) .

Investigations into these areas could yield important insights into the fundamental biology of Acvr2b and identify novel therapeutic targets.